| Literature DB >> 31671780 |
Kristin Andrud1, Hong Xing2, Bjarne Gabrielsen3, Linda Bloom4, Vladimir Mahnir5, Stephen Lee6, Benedict T Green7, Jon Lindstrom8, William Kem9.
Abstract
Three major forms of the nicotinic agonist toxin anabaseine (cyclic iminium, cyclic imine and the monocationic open-chain ammonium-ketone) co-exist in almost equal concentrations at physiological pH. We asked the question: Which of these forms is pharmacologically active? First, we investigated the pH dependence of anabaseine inhibition of [3H]-methylcarbamylcholine binding at rat brain α4β2 nicotinic acetylcholine receptors (nAChRs). These experiments indicated that one or both monocationic forms interact with the orthosteric binding site for ACh. However, since they occur at equal concentrations near physiological pH, we employed another approach, preparing a stable analog of each form and examining its agonist activities and binding affinities at several vertebrate brain and neuromuscular nAChRs. Only 2-(3-pyridyl)-1,4,5,6-tetrahydropyrimidine monohydrogen chloride (PTHP), the cyclic iminium analog, displayed nAChR potencies and binding affinities similar to anabaseine. The cyclic imine analog 2,3'-bipyridyl and the open-chain ammonium-ketone analog 5-methylamino-1-(3-pyridyl)-1-pentanone (MAPP), displayed ≤1% of the activity predicted if the one form was solely active. The lower potency of weakly basic 2,3'-bipyridyl can be explained by the presence of a small concentration of its monocationic form. Since the open chain ammonium-ketone monocationic form of anabaseine has some structural similarity to the neurotransmitter GABA, we also tested the ability of anabaseine and its 1,2-dehydropyrrolidinyl analog myosmine to activate a mammalian GABAA receptor, but no activity was detected. We conclude that the monocationic cyclic iminium is the form which avidly binds and activates vertebrate nAChRs.Entities:
Keywords: acetylcholine; alkaloid; anabaseine; bipyridyl; cholinergic; nicotine; nicotinic acetylcholine receptor; ring-chain tautomerism; toxin
Mesh:
Substances:
Year: 2019 PMID: 31671780 PMCID: PMC6891768 DOI: 10.3390/md17110614
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1A: Structures of the three major forms of anabaseine that exist in dynamic equilibrium under physiological conditions; B: Anabaseine analogs synthesized to represent the particular form shown above. MAPP (also called N-methyl anabaseine) can still occur as a cyclic imine or iminium, but the equilibrium greatly (≥ 20-fold) favors the ammonium-ketone monocation form.
Figure 2Concentrations of the three major forms of anabaseine as a function of pH as determined by UV spectrophotometry [32]. Left Ordinate: Concentration of each form expressed as % of the total anabaseine concentration. The red curve is the estimated cyclic imine concentration and the blue curve is the concentration of the cyclic iminium or the monocationic ammonium-ketone form of anabaseine (Assuming that KH = 1.0, the concentrations of these ionized forms are equal). Right ordinate: pH dependence of anabaseine inhibition of [3H]-MCC binding to rat brain α4β2 receptors (Standard error bars included). Anabaseine inhibition (mean ± SEM) at each pH was the average of six replicate measurements.
Figure 3Activation of the human α4β2 neuronal nAChR expressed in tsA201 cells as measured by membrane depolarization using the FlexStation assay. Each point generally is the mean of four separate measurements. All responses were normalized with respect to the response of the cells to 0.5 μM epibatidine. Potency and efficacy estimates from these curves are found in Table 1.
Figure 4Activation of the human fetal (TE671 cells) skeletal muscle nAChR by the various stable anabaseine analogs measured by membrane depolarization using the FlexStation assay. Each point is generally the mean of four separate measurements. Responses were normalized to the 5 μM epibatidine response. Potency and efficacy estimates from these curves are found in Table 1.
Figure 5Investigation of possible activation of the human GABAA receptor measured by membrane depolarization using a FlexStation assay. Each point is the mean of three separate measurements. All responses were normalized with respect to the response of the cells to 1 mM μM GABA. The EC50 value for GABA was 3.0 µM (95% confidence interval = 1.8–5.1 μM).
Potencies and affinities characterizing the interactions of anabaseine and its stable analogs with several neuronal and neuromuscular nAChRs.
| Neuronal nAChR | Neuromuscular nAChR | ||||
|---|---|---|---|---|---|
| Human | Rat | Rat | Human |
| |
| Compound | α4β2 | α4β | α7 | TE671 | Electric Organ |
| μM: | EC50 | Ki 1 | Ki 2 | EC50 | IC50 3 |
| Anabaseine | 2.85 ± 1.0 | 0.096 ± 0.01 | 1.87 ± 0.10 | 1.2 ± 0.0 | 0.29 ± 0.18 |
| PTHP | 3.64 ± 1.2 | 0.38 ± 0.07 | 1.54 ± 0.76 | 1.7 ± 0.3 | 0.47 ± 0.01 |
| 2,3′-Bipyridyl | >1000 | >50 | >2300 | 660 ± 60 | 343 ± 48 |
| MAPP | >2000 | 10 | >2000 | >1000 | >500 |
1 Determined by displacement of [3H]-cytisine; 2 Determined by displacement of [125I]α-bungarotoxin; 3 Determined by inhibition of the rate of binding of [125I]-α-bungarotoxin.